Clearmind Medicine Announces Clinical Research Collaboration With Johns Hopkins University To Evaluate CMND-100 In Patients With Alcohol Use Disorder
Portfolio Pulse from Benzinga Newsdesk
Biotech company Clearmind Medicine Inc. has announced a Clinical Trial Agreement with Johns Hopkins University School of Medicine to conduct a Phase I/IIa clinical trial of its proprietary MEAI-based CMND-100. The trial aims to evaluate the potential of CMND-100 in treating patients with Alcohol Use Disorder.
September 06, 2023 | 1:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Clearmind Medicine's partnership with Johns Hopkins University for a clinical trial could potentially boost the company's reputation and stock value if the trial results are positive.
The partnership with a reputable institution like Johns Hopkins University for a clinical trial could potentially increase investor confidence in Clearmind Medicine. If the trial results are positive, it could lead to increased demand for the company's stock, thereby driving up its price.
CONFIDENCE 70
IMPORTANCE 80
RELEVANCE 100